CICON 2019 Conference Program



WEDNESDAY, September 25, 2019  


10:30 am

Registration desk opening


1:00 pm - 2:00 pm

Welcome

1:00 pm - 1:10 pm

Grand Opening. Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France

1:10 pm - 2:00 pm

Keynote Lecture: Immunological response of human cancers to PD-1 blockade. Ton Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands


2:00 pm - 4:00 pm

Session 1: Cancer Prevention and Lifestyle Factors in Oncoimmunology

Session Chairperson: Olivera J. Finn

2:00 pm - 2:35 pm

Targets of spontaneous immunosurveillance as vaccine antigens for cancer prevention. Olivera J. Finn, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

2:35 pm - 3:05 pm

Caloric restriction mimetics that support anticancer immunosurveillance. Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France

3:05 pm - 3:30 pm

Nociceptors control functions of dendritic cells. Pavel Hanc*, Harvard Medical School, Boston, Massachusetts

3:30 pm - 4:00 pm

Stress compromises therapy-induced anti- tumor immunity. Yuting Ma, Suzhou Institute of Systems Medicine, Suzhou, China


4:00 pm - 4:30 pm

Coffee break


4:30 pm - 6:30 pm

Session 2: Combination Therapies with Immune Checkpoint Blockers

Session Chairperson: Alexander Eggermont

4:30 pm - 5:05 pm

Lessons from the IO-Melanoma-revolution and it’s roll out across multiple tumor types. Alexander Eggermont, Gustave Roussy Cancer Center, Villjuif, France

5:05 pm - 5:25 pm

Reprogramming the tumor microenvironment by activation of p53 enhances antitumor effects of immune checkpoint blockade in preclinical models. Arnab Ghosh*, Memorial Sloan Kettering Cancer Center, New York City, New York

5:25 pm - 6:00 pm

Combination immunotherapy of cancer involving therapeutic vaccination. Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands

6:00 pm - 6:30 pm

Harnessing innate immunity in cancer therapy. Eric Vivier, Centre d'immunologie de Marseille-Luminy, Marseille, France


starting from 6:30 pm

Cocktail reception



THURSDAY, SEPTEMBER 26, 2019

8:00 am - 9:00 am

William B. Coley Lecture

Elizabeth M. Jaffee, Johns Hopkins University School of Medicine, Baltimore, Maryland


9:00 am - 11:00 am

Session 3: T Cell Exhaustion – mechanisms: Resistance Mechanisms

Session Chairperson: W. Nicholas Haining

9:00 am - 9:25 am

Functional genomic approaches for understanding the immune response to cancer. W. Nicholas Haining, Dana-Farber Cancer Institute, Boston, Massachusetts

9:25 am - 9:50 am

Intoxication causes T-cell exhaustion in chronic infection. Dietmar Zehn, Technical University of Munich, Freising, Germany

9:50 am - 10:10 am

CD226 absence affects TCR responsiveness and restrains tumor infiltrating T lymphocyte functions. Ludovic Martinet*, Centre de recherche en Cancérologie de Toulouse, Toulouse, France

10:10 am - 10:35 am

Acquired T cell function and dysfunction in response to immunotherapy. David Brooks, Princess Margaret Cancer Centre, Toronto, Canada

10:35 am - 11:00 am

A novel class of fully human bispecific antibodies for cancer immunotherapy. Dimitris Skokos, Regeneron Pharmaceuticals, Tarrytown, New York


11:00 am - 1:00 pm

Session 4: Immunotherapies, Non-Cell-Based

Session Chairperson: Ira Mellman

11:00 am - 11:25 am

Mechanistic basis of cancer immunotherapy: checkpoints at 10. Ira Mellman, Genentech, San Francisco, California

11:25 am - 11:50 am

Title not available. Ugur Sahin, BioNTech, Mainz, Germany

11:50 am - 12:15 pm

Systems Immunology in IO: A view from the Parker Institute. Nikesh Kotecha, Parker Institute for Cancer Immunotherapy, San Francisco, California

12:15 pm - 12:40 pm

Overcoming the Immunosuppressive prostate tumor microenvironment. Sumit Subudhi*, The University of Texas MD Anderson Cancer Center, Houston, Texas

12:40 pm - 1:00 pm

Vaccination against a neoepitope whose expression is driven by acquired resistance to oncolytic virotherapy prevents VSV- resistant tumour recurrence. Richard Vile, Mayo Clinic, Rochester, Minnesota


1:00 pm - 3:00 pm

Lunch and Poster Session A and Exhibits

1:00 pm - 3:00 pm

Poster Session A

1:15 pm - 2:35 pm

1:15 pm - 1:35 pm

Harnessing innate immunity in cancer. Eric Vivier, Innate Pharma, Marseille, France

1:35 pm - 1:55 pm

Characterization of the tumor immune microenvironment. Bianca Heemskerk, Miltenyi Biotec, Bergisch Gladbach, Germany

1:55 pm - 2:15 pm

Protective spontaneous humoral responses in ovarian cancer. Jose Conejo-Garcia, Moffitt Cancer Center, Florida, USA

2:15 pm - 2:35 pm

T cell gene transfer and genome editing in cancer immunotherapy. Chiara Bonini, University Vita-Salute San Raffaele, Milan, Italy


3:00 pm - 4:30 pm

Session 5: Immunotherapies, Cell Based

Session Chairperson: Helen E. Heslop

3:00 pm - 3:25 pm

Towards the next generation of cancer vaccines. Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands

3:25 pm - 3:40 pm

Genome-Wide CRISPR screens reveal SOCS-1 as a dominant intrinsic checkpoint of CD4 T cells quorum sensing. Laurie Menger, Curie Institute, Paris, France

3:40 pm - 4:05 pm

Targeting tumors with native and chimeric receptors. Helen E. Heslop, Baylor College of Medicine, Houston, Texas

4:05 pm - 4:30 pm

Engineering next-generation T cell therapies for solid tumors. Kole Roybal, University of California San Francisco, San Francisco, California


4:30 pm - 5:00 pm

Coffee break


5:00 pm - 6.30 pm

Session 6: New Targets and Concepts

Session Chairperson: Ellen Puré

5:00 pm - 5:20 pm

Targeting stroma to treat cancer and fibrosis. Ellen Puré, University of Pennsylvania, Philadelphia, Pennsylvania

5:20 pm - 5:50 pm

Cellular conversations that control cancer. Thea D. Tlsty, University of California San Francisco, San Francisco, California

5:50 pm - 6:05 pm

CD24 signaling through macrophage Siglec-10 is a new target for cancer immunotherapy. Amira Barkal*, Stanford University, Stanford, California

6:05 pm - 6:30 pm

Antitumor T cells, you are what you eat. Susan Kaech, Salk Institute for Biological Studies, La Jolla, California

6:30 pm - 8:00 pm

Drinks and Poster Session A (continued)



Friday, SEPTEMBER 27, 2019

9:00 am - 11:00 am

Session 7: Tumor Antigens

Session Chairperson: Robert D. Schreiber

9:00 am - 9:25 am

UVB-induced tumor heterogeneity diminishes immune response in melanoma. Yardena Samuels, Weizmann Institute of Science, Rehovot, Israel

9:25 am - 9:55 am

The molecular cell biology of immune control and escape of tumors. Robert D. Schreiber, Washington University School of Medicine, St Louis, Missouri

9:55 am - 10:15 am

Integrated proteogenomic deep sequencing and analytics accurately identify the tumor non-canonical immunopeptidome. Chloe Chong*, Ludwig Institute for Cancer Research, Lausanne, Switzerland

10:15 am - 10:40 am

Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences. Sjoerd van der Burg, Leiden University, Leiden, The Netherlands

10:40 am - 11:00 am

Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Lorenzo Galluzzi, Weill Cornell Medical College, New York City, New York


11:00 am - 1:00 pm

Session 8: Vaccination Strategies

Session Chairperson: Özlem Türeci

11:00 am - 11:25 am

New insights on the mechanisms regulating in situ vaccination by radiotherapy. Sandra Demaria, Weill Cornell Medical College, New York City, New York

11:25 am - 11:50 am

Cancer vaccines & combination with “standard of care” therapies. Sebastian Kreiter, BioNTech AG, Mainz, Germany

11:50 am - 12:15 pm

Title not available. Özlem Türeci, BioNTech AG, Mainz, Germany

12:15 pm - 12:30 pm

Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients who progressed on prior anti-PDx therapy. Elizabeth Evans*, Vaccinex, Rochester, New York

12:30 pm - 12:45 pm

Novel epitope derived from PBK (PDZ- binding kinase), a cancer testis antigen, allows CD8+ T cell recognition of pediatric brain tumors. Michelle R. Brault*, Fred Hutchison Cancer Research Center, Seattle, Washington

12:45 pm - 1:00 pm

Ribosome profiling predicts novel unannotated open reading frames that contribute peptides to the MHC class I immunopeptidome in healthy and cancer cells and can be a source of neoantigens. Tamara Ouspenskaia*, Broad Institute, Cambridge, Massachusetts


1:00 pm - 3:00 pm

Lunch and Poster Session B and Exhibits

1:00 pm - 3:00 pm

Poster Session B

1:15 pm - 2:45 pm

Plenary Lunch Meeting 2. MEET-THE-EDITORS: Science, Nature Medicine, Cancer Immunology Research, OncoImmunology & others 


3:00 pm - 4:30 pm

Session 9: New Trends in Technology & Informatics

Session Chairperson: E. John Wherry

3:00 pm - 3:25 pm

MHC genotype shapes the oncogenic mutational landscape. Hannah Carter, University of California San Diego, La Jolla, California

3:25 pm - 3:50 pm

Mechanisms of T cell exhaustion and role in immunotherapy of cancer. E. John Wherry, Institute for immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

3:50 pm - 4:15 pm

Proteogenomics and immunopeptidomics for the development of personalized cancer immunotherapy. Michal Bassani-Sternberg, Lausanne University Hospital, Lausanne, Switzerland

4:15 pm - 4:30 pm

Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma. Livnat Jerby*, Broad Institute, Cambridge, Massachusetts


4:30 pm - 5:00 pm

Coffee break


5:00 pm - 6:30 pm

Session 10: TME analysis

Session Chairperson: Miriam Merad

5:00 pm - 5:25 pm

Context dependent impact of B cells on cancer clinical outcome. Wolf Hervé Fridman, Centre de Recherche des Cordeliers, Paris, France

5:25 pm - 5:50 pm

Learning the rules of human cancer immunity. Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, Massachusetts

5:50 pm - 6:15 pm

Myeloid cell contribution to antitumor immunity. Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

6:15 pm - 6:30 pm

Identification of a DC1 immuno-regulatory module that is associated with tumor antigen uptake and partially driven by TAM receptor AXL. Barbara B. Maier*, Icahn School of Medicine at Mount Sinai Hospital, New York City, New York

6:30 pm - 8:00 pm

Drinks and Poster Session B (continued)


8:00 pm - 11:30 pm

Gala dinner

Boarding: 8:00 p.m. - 9:00 p.m. Expected return to the dock: 11:30 p.m.



Saturday, September 28, 2019

9:00 am - 11:00 am

Session 11: IO Crosstalk and Metabolism

Session Chairperson: Ursula Grohmann

9:00 am - 9:30 am

Metabolic interactions between deleterious immune populations and the tumor microenvironment. Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania

9:30 am - 9:50 am

Immunometabolism modulation by PSGL-1 signaling in tumor-specific T cells. Jennifer L. Hope*, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California

9:50 am - 10:20 am

An Intracellular Spatial Dynamics Dictates the Catalytic Versus Signaling Function of Immunoregulatory IDO1. Ursula Grohmann, University of Perugia, Perugia, Italy

10:20 am - 10:40 am

Neoantigen-driven remodelling of the T cell landscape in NSCLC. James L. Reading*, University College London, London, UK

10:40 am - 11:00 am

Incessant ER stress responses promote dendritic cell dysfunction in ovarian cancer. Chang-Suk Chae*, Weill Cornell Medical College, New York City, New York


11:00 am - 1:00 pm

Session 12: Microbiota in Oncoimmunology

Session Chairperson: Jennifer A. Wargo

11:00 am - 11:30 am

Molecular mimicry between cancer and enterophage antigens: relevance for PD-1 blockade. Laurence Zitvogel, Gustave Roussy Cancer Center, Villejuif, France

11:00 am - 11:45 am

Intraepithelial lymphocytes undertake skin immunosurveillance by sensing Skint1. Duncan R. McKenzie*, The Francis Crick Institute, London, UK

11:45 am - 12:15 pm

Targeting the microbiome in cancer immunotherapy. Giorgio Trinchieri, National Cancer Institute, Frederick, Maryland

12:15 pm - 12:30 pm

Investigating immune-microbiota interaction in genetically engineered mouse model of lung cancer. Chengcheng Jin*, Massachusetts Institute of Technology, Cambridge, Massachusetts

12:30 pm - 1:00 pm

The role of the microbiome in response and toxicity to therapy. Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas


*proffered abstract